• Peter Lindner
  • Andreas Plückthun
Part of the Springer Lab Manuals book series (SLM)


The term “miniantibodies” describes artificial multivalent or multispecific recombinant antibody fragments. They resemble natural antibodies in carrying two or four binding sites with a flexible arrangement and a long “wing span” but they are much smaller, as they consist only of fusions of a scFv to an oligomerization module. Applications of multivalent and bispecific antibody fragments in a variety of formats have been reviewed (Plückthun and Pack 1997; Carter and Merchant 1997). Approaches to quantify the avidity gain achieved by the multivalency effect present in all the described miniantibody models have been reported (Crothers and Metzger 1972, Plückthun and Pack 1997, Müller et al. 1998b).


Antibody Fragment Leucine Zipper Coiled Coil scFv Fragment Body Fragment 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arndt KM, Pelletier JN, Müller KM, Alber T, Michnick SW, Plückthun A (2000) A heterodimeric coiled-coil peptide pair selected in vivo from a designed library-versuslibrary ensemble. T Mol Biol 295:627–639CrossRefGoogle Scholar
  2. Bass S, Gu Q, Christen A (1996) Multicopy suppressors of prc mutant Escherichia coli include two HtrA (DegP) protease homologs (HhoAB), DksA, and a truncated R 1 pA. J Bacteriol 178: 1154–1161PubMedGoogle Scholar
  3. Bass S, Gu Q, Christen A, Bothrnann H, Plückthun A (1998) Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nature Biotechnol 16:376–380CrossRefGoogle Scholar
  4. Bothmann H, Plückthun A (2000) The periplasmic Escherichia coli peptidylprolyl cis, trans-isomerase FkpA. I. Increased functional expresssion of antibody fragments with and without cis-prolines. J Biol Chem 275:17100–17105PubMedCrossRefGoogle Scholar
  5. Burton DR (1985) Immunoglobulin G: functional sites. Mol Immunol 22:161–206PubMedCrossRefGoogle Scholar
  6. Carter P, Merchant AM (1997) Engineering antibodies for imaging and therapy. Curr Opinion Biotechnol 8:449–454CrossRefGoogle Scholar
  7. Crothers DM, Metzger H (1972) The influence of polyvalency on the binding properties of antibodies. Immunochemistry 9:341–357PubMedCrossRefGoogle Scholar
  8. Dürr E, Jelesarov I, Bosshard HR (1999) Extremely fast folding of a very stable leucine zipper with a strengthened hydrophobic core and lacking electrostatic interactions between helices. Biochemistry 38:870–880PubMedCrossRefGoogle Scholar
  9. Eisenberg D, Wilcox W, Eshita SM, Pryciak PM, Ho SP and DeGrado WF (1986) The design, synthesis, and crystallization of an alpha-helical peptide. Proteins 1:16–22PubMedCrossRefGoogle Scholar
  10. Ge L, Knappik A, Pack P, Freund C, Plückthun A (1995) Expressing antibodies in Escherichia coli. In: Antibody Engineering, 2nd edition, Borrebaeck CAK (ed) Oxford University Press, pp 229–266Google Scholar
  11. Harbury PB, Zhang T, Kim PS, Alber T (1993) A switch between two-, three-, and fourstranded coiled coils in GCN4 leucine zipper mutants. Science 262:1401–1407PubMedCrossRefGoogle Scholar
  12. Hill RB, DeGrado WF (1998) Solution structure of a2D, a nativelike de novo designed protein. J Am Chem Soc 120:1138–1145CrossRefGoogle Scholar
  13. Horn U, Strittmatter W, Krebber A, Knüpfer U, Kujau M, Wenderoth R, Müller K, Matzku S, Plückthun A, Riesenberg D (1996) High volumetric yields of functional dimeric miniantibodies in Escherichia coli, using an optimized expression vector and high-cell-density fermentation under non-limited growth conditions. (1996) Appl Microbiol Biotechnol 46:524–532CrossRefGoogle Scholar
  14. Huston JS, Mudgett-Hunter M, Tai M-S, McCartney J, Warren F, Haber E, Oppermann H (1991) Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 203:46–88PubMedCrossRefGoogle Scholar
  15. Jeffrey PD, Gorina S, Pavletich NP (1995) Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 Angstroms. Science 267:1498–1502PubMedCrossRefGoogle Scholar
  16. Jung S, Plückthun A (1997) Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Engineering 10:959–966PubMedCrossRefGoogle Scholar
  17. Knappik A, Plückthun A (1994) An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments. Bio Techniques 17:754–761Google Scholar
  18. Knappik A, Plückthun A (1995) Engineered turns of a recombinant antibody improve its in vivo folding. Protein Engineering 8:81–89PubMedCrossRefGoogle Scholar
  19. Krebber A, Bornhauser S, Burmester J, Honegger A, Willuda J, Bosshard HR, Plückthun A (1997) Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Irrmrrmmunol Meth 201:35–55CrossRefGoogle Scholar
  20. Lindner P, Guth B, Wülfing C, Krebber C, Steipe B, Müller F, Plückthun A (1992) Purification of native proteins from the cytoplasm and periplasm of Escherichia coli using IMAC and histidine tails: a comparison of proteins and protocols. Methods 4:41–56CrossRefGoogle Scholar
  21. Lindner P, Bauer K, Krebber A, Nieba L, Kremmer E, Krebber C, Honegger A, Klinger B, Mocikat R, Plückthun A (1997) Specific detection of his-tagged proteins with recombinant anti-his tag scFv-phosphatase or scFv-phage fusions. Bio Techniques 22:140–149Google Scholar
  22. Maurer R, Meyer BJ, Ptashne M (1980) Gene regulation at the right operator (OR) of bacteriophage I. OR3 and autogenous negative control by repressor. J Mol Biol 139:147–161PubMedCrossRefGoogle Scholar
  23. Müller KM, Arndt KM, Strittmatter W, Plückthun A (1998a) The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett 422:259–264PubMedCrossRefGoogle Scholar
  24. Müller KM, Arndt KM, Plückthun A (1998b) Model and simulation of multivalent binding to fixed ligands. Anal Biochem 261:149–158PubMedCrossRefGoogle Scholar
  25. Müller KM, Arndt KM, Plückthun A (1998c) A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett 432:45–49PubMedCrossRefGoogle Scholar
  26. Müller KM, Arndt KM, Alber T (2000) Protein Fusions to coiled-coil domains. Methods Enzymol 328: 261–282PubMedCrossRefGoogle Scholar
  27. Nieba L, Honegger A, Krebber C, Plückthun A (1997) Disrupting tne hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Engineering 10:435–444PubMedCrossRefGoogle Scholar
  28. O’Shea EK, Klemm JD, Kim PS, Alber T (1991) X-ray structure of the GCN4 leucine zipper, a two-stranded, parallel coiled coil. Science 254:539–544PubMedCrossRefGoogle Scholar
  29. Pack P (1994) PhD Thesis, Universität München, GermanyGoogle Scholar
  30. Pack P, Knappik A, Krebber C, Plückthun A (1992) Mono- and bivalent antibody fragments produced in E. coli: binding properties and folding in vivo. In: Harnessing Biotechnology for the 21st Century. American Chemical Society Conference Proceedings Series. Ladisch MR and Bose A (eds.) ACSGoogle Scholar
  31. Pack P, Plückthun A (1992) Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric Fv fragments with high avidity in Escherichia coli. Biochemistry 31:1579–1584PubMedCrossRefGoogle Scholar
  32. Pack P, Kujau M, Schroeckh V, Knüpfer U, Wenderoth R, Riesenberg D, Plückthun A (1993) Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology 11:1271–1277PubMedGoogle Scholar
  33. Pack P, Müller K, Zahn R, Plückthun A (1995) Tetravalent miniantibodies with a high avidity assembling in Escherichia coli. J Mol Biol 246:28–34PubMedCrossRefGoogle Scholar
  34. Plückthun A and Pack P (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3: 83–105PubMedCrossRefGoogle Scholar
  35. Plückthun A, Krebber A, Krebber C, Horn U, Knüpfer U, Wenderoth R, Nieba L, Proba K, Riesenberg D (1996) Producing antibodies in Escherichia coli: From PCR to fermentation. In: Antibody Engineering: A Practical approach. McCafferty J and Hoogenboom HR (eds), IRL press, Oxford, pp 203–252Google Scholar
  36. Rheinnecker M, Hardt C, Ilag LL, Kufer P, Gruber R, Hoess A, Lupas A, Rottenberger C, Plückthun A, Pack P (1996) Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. J Immunol 157:2989–2997PubMedGoogle Scholar
  37. Rudolph R, Lilie H (1996) In vitro folding of inclusion body proteins. FASEB J 10:49–56PubMedGoogle Scholar
  38. Schroeckh V, Kujau M, Knüpfer U, Wenderoth R, Mörbe J, Riesenberg D (1996) Formation of recombinant proteins in Escherichia coli under control of a nitrogen regulated promoter at low and high cell densities. J. Biotechnol. 49:45–58Google Scholar
  39. Willuda J, Honegger A, Waibel R, Schubiger A, Stahel R, Zangemeister-Wittke U, Plückthun A (1999) High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Research 59:5758–5767PubMedGoogle Scholar
  40. Yanisch-Perron C, Vieira J, Messing J (1985) Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M 13mp 18 and pUC19 vectors. Gene 33:103–119PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2001

Authors and Affiliations

  1. 1.Biochemisches InstitutUniversität ZürichZürichSwitzerland

Personalised recommendations